NCT04840342View on ClinicalTrials.gov

MR Antagonist and LSD1

PHASE4RecruitingINTERVENTIONAL

Enrollment

300

Participants

Timeline

Start Date

February 3, 2022

Primary Completion Date

February 28, 2026

Study Completion Date

June 30, 2026

Conditions

HypertensionMineralocorticoid Excess

Interventions

DRUG

Eplerenone

Dose escalations of eplerenone 50, 100, or 200mg

DRUG

Amlodipine

Dose escalations of amlodipine 2.5, 5, or 10mg

Trial Locations (1)

02115

RECRUITING

Brigham and Women's, Boston

All Listed Sponsors

lead

Brigham and Women's Hospital

OTHER